JOP20190254A1 - مركبات مضادة للأورام - Google Patents

مركبات مضادة للأورام

Info

Publication number
JOP20190254A1
JOP20190254A1 JOP/2019/0254A JOP20190254A JOP20190254A1 JO P20190254 A1 JOP20190254 A1 JO P20190254A1 JO P20190254 A JOP20190254 A JO P20190254A JO P20190254 A1 JOP20190254 A1 JO P20190254A1
Authority
JO
Jordan
Prior art keywords
antitumoral compounds
antitumoral
compounds
formula
cancer
Prior art date
Application number
JOP/2019/0254A
Other languages
English (en)
Inventor
Solloso Andres Francesch
Barrasa Valentin Martinez
Marchante Maria Del Carmen Cuevas
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of JOP20190254A1 publication Critical patent/JOP20190254A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

مركب له الصيغة العامة I، حيث أن X ، R1 – R4 تأخذ معانى مختلفة، للإستخدام فى معالجة السرطان. الصيغة I
JOP/2019/0254A 2017-04-27 2017-06-16 مركبات مضادة للأورام JOP20190254A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
EP17382497 2017-07-26

Publications (1)

Publication Number Publication Date
JOP20190254A1 true JOP20190254A1 (ar) 2019-10-27

Family

ID=62063080

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0254A JOP20190254A1 (ar) 2017-04-27 2017-06-16 مركبات مضادة للأورام

Country Status (37)

Country Link
US (4) US10538535B2 (ar)
EP (5) EP4047002B1 (ar)
JP (5) JP6501946B2 (ar)
KR (3) KR102492283B1 (ar)
CN (4) CN114751920A (ar)
AU (4) AU2018260314C1 (ar)
BR (1) BR112019022282A2 (ar)
CA (1) CA3061518A1 (ar)
CL (1) CL2019003057A1 (ar)
CO (1) CO2019011967A2 (ar)
CY (3) CY1121885T1 (ar)
DK (5) DK3615544T3 (ar)
EC (1) ECSP19083967A (ar)
ES (5) ES2741901T3 (ar)
FI (3) FI4047002T3 (ar)
HK (2) HK1255938B (ar)
HR (5) HRP20230433T1 (ar)
HU (5) HUE062157T2 (ar)
IL (3) IL270153B2 (ar)
JO (1) JOP20190254A1 (ar)
LT (5) LT4101855T (ar)
MA (2) MA44020B1 (ar)
MD (5) MD3615544T2 (ar)
ME (2) ME03467B (ar)
MX (3) MX2019012812A (ar)
MY (1) MY198004A (ar)
PH (1) PH12019550224A1 (ar)
PL (5) PL3395820T3 (ar)
PT (2) PT3395820T (ar)
RS (5) RS64174B1 (ar)
SG (2) SG10201913300YA (ar)
SI (5) SI3615544T1 (ar)
TN (2) TN2019000211A1 (ar)
TW (3) TWI742273B (ar)
UY (1) UY37706A (ar)
WO (1) WO2018197663A1 (ar)
ZA (1) ZA201907119B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
EP4061372A1 (en) * 2019-11-21 2022-09-28 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
CR20220581A (es) 2020-04-21 2023-01-09 Pharma Mar Sa Conjugados de anticuerpos de fármacos
WO2021218896A1 (zh) * 2020-04-26 2021-11-04 江苏恒瑞医药股份有限公司 海鞘素类衍生物及其制备方法与医药用途
CA3218171A1 (en) 2021-05-19 2022-11-24 Carmen KAHATT Dosage regimens for ecubectedin

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
HU201672B (en) 1984-12-28 1990-12-28 Conpharm Ab Process for producing pharmaceutical compositions comprising podophyllotoxin
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
EP0220453B1 (de) 1985-09-20 1992-04-15 Cernitin S.A. Verwendung von Pflanzenpollenextrakten zur Herstellung von das Wachstum von Tumorzellen hemmenden pharmazeutischen Präparaten und Verfahren zu ihrer Herstellung
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
JP2562162B2 (ja) 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン７２９、７４３、７４５、７５９ａ、７５９ｂおよび７７０
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
ATE83480T1 (de) 1988-09-05 1993-01-15 Sankyo Co Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
WO1990005731A1 (en) 1988-11-24 1990-05-31 University Of Queensland Cytotoxic macromolecules
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (en) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
KR950702994A (ko) 1992-08-12 1995-08-23 로렌스 티. 웰츠 탁솔과 복합된, 단백질 키나제 억제제 및 관련 화합물(protein kinase inhibitors and related compounds combined with taxol)
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
ES2262175T3 (es) 1996-10-24 2006-11-16 The Board Of Trustees Of The University Of Illinois Estudios semisinteticos para dar analogos de didemnina.
PT956033E (pt) 1996-10-24 2003-10-31 Univ Illinois SíNTESE TOTAL DE ANALOGOS AMINO HIP DE DIDEMNINA A
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
AU740598B2 (en) 1997-05-07 2001-11-08 William J. Crumb Aplidine as an L-type calcium channel enhancer
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
WO1999051238A1 (en) 1998-04-06 1999-10-14 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
ES2248999T3 (es) 1998-05-05 2006-03-16 Pharma Mar, S.A. Cultivo de animales marinos sesiles.
AU759281B2 (en) 1998-05-11 2003-04-10 Pharma Mar S.A. Metabolites of ecteinascidin 743
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
SK287762B6 (sk) 1999-11-15 2011-09-05 Pharma Mar, S. A. Použitie aplidínu na prípravu farmaceutického prostriedku na liečenie rakoviny
AU783562B2 (en) 2000-01-19 2005-11-10 Trustees Of Columbia University In The City Of New York, The Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
BR0108448A (pt) 2000-02-16 2003-04-01 Pharma Mar Sa Derivados de tetraidrofuril óxi-e amino-substituìdos com atividade antitumor
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
NZ521844A (en) 2000-04-07 2004-07-30 Univ Pennsylvania Tamandarin and didemnin analogs having deoxo-proline residue or dehydro-proline residue and methods of making and use thereof
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
JP5219323B2 (ja) 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
IL153096A0 (en) 2000-06-06 2003-06-24 Pharma Mar Sa Spisulosine analogs and pharmaceutical compositions containing the same
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
US7320981B2 (en) 2000-07-11 2008-01-22 Pharma Mar, S.A. Variolin derivatives as anti-cancer agents
WO2002005868A2 (en) 2000-07-13 2002-01-24 Transurgical, Inc. Thermal treatment methods and apparatus with focused energy application
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
JP2004510824A (ja) 2000-10-12 2004-04-08 ファルマ・マール・ソシエダード・アノニマ ガンの治療
CN1479622A (zh) 2000-10-12 2004-03-03 联合使用阿普里汀和肌肉保护剂来治疗癌症
JP2004512370A (ja) 2000-10-31 2004-04-22 ファルマ・マール・ソシエダード・アノニマ カハラリドｆ
WO2002036135A2 (en) 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
US20040047807A1 (en) 2001-01-24 2004-03-11 Dominik Meyer Use of neurotoxic substances in producing a medicament for treating joint pains
CN1489466A (zh) 2001-01-25 2004-04-14 ����˹�ж�-����˹˹������˾ 包含埃博霉素类似物的非肠道制剂
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
WO2003033013A1 (en) 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
EP1435990A1 (en) 2001-10-19 2004-07-14 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
HUP0401903A3 (en) 2001-10-19 2008-07-28 Pharma Mar Improved use of et-743 in cancer thereapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
EP1551315A2 (en) * 2002-10-04 2005-07-13 St. Jude Medical ATG, Inc. Self-expanding exterior connectors for creating anastomoses to small-diameter vessels and methods of use
JP2006501947A (ja) * 2002-10-08 2006-01-19 エスディージーアイ・ホールディングス・インコーポレーテッド 整形外科移植片の挿入装置と技法
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
ES2357644T3 (es) 2002-10-18 2011-04-28 Pharma Mar, S.A.U. Compuesto 4-metilhexanoico kahalalido f.
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
ATE472338T1 (de) 2003-02-20 2010-07-15 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
JP2006519848A (ja) 2003-03-12 2006-08-31 ファルマ・マール・ソシエダード・アノニマ 改良された抗腫瘍治療
JP4584245B2 (ja) 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 多発性骨髄腫治療用のアプリジン
CA2519234A1 (en) 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
EP1651633A1 (en) 2003-07-25 2006-05-03 Novartis AG Substituted lactams and their use as anti-cancer agents
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
WO2005035524A1 (en) 2003-10-09 2005-04-21 Abbott Laboratories Pyrrolidinyl urea derivatives as angiogensis inhibitors
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
ES2314470T3 (es) 2003-11-13 2009-03-16 Pharma Mar, S.A.U. Combinacion de et-743 con un profarmaco de 5-fluorouracilo para el tratamiento del cancer.
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2545054A1 (en) 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
JP2008505862A (ja) 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
AU2005288696A1 (en) 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RU2359700C2 (ru) 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
PT1658848E (pt) 2004-10-29 2007-11-05 Pharma Mar Sa Formulações contendo ecteinascidina e um dissacarídeo
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
EA013160B1 (ru) 2005-05-03 2010-02-26 Фарма Мар, С.А. Противоопухолевые тетрагидропиримидины
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
RU2008107974A (ru) 2005-08-02 2009-09-10 Фарма Мар, С.А. (Es) Гены, участвующие в биосинтезе тиокоралина и его гетерологичном продуцировании
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
US20090170860A1 (en) 2005-11-25 2009-07-02 Pharma Mar, S.A., Sociedad Unipersonal Use of PARP-1 Inhibitors
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
HUE028055T2 (en) 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
CA2652035A1 (en) 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
PL2032551T3 (pl) 2006-06-16 2012-01-31 Pharma Mar Sa Przeciwnowotworowe związki dihydropiran-2-onu
CA2703026A1 (en) 2007-10-19 2009-04-23 Rafael Rosell Costa Prognostic molecular markers for et-743 treatment
US20100240595A1 (en) 2007-10-19 2010-09-23 Pharma Mar ,S.A. Improved Antitumoral Treatments
AU2008312400A1 (en) 2007-10-19 2009-04-23 Albert Einstein College Of Medicine Of Yeshiva University Improved antitumoral treatments
CA2708080C (en) 2007-12-14 2016-06-14 Pharma Mar, S.A. Antitumoral compounds
CA2710087C (en) 2007-12-20 2015-06-02 Pharma Mar, S.A. Antitumoral compounds
WO2009095480A1 (en) 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
JP2011513429A (ja) 2008-03-07 2011-04-28 ファルマ・マール・ソシエダード・アノニマ 改善された抗癌治療法
JP2011513370A (ja) 2008-03-07 2011-04-28 ファルマ・マール・ソシエダード・アノニマ 改善された抗腫瘍治療法
AU2009246130A1 (en) 2008-05-16 2009-11-19 Pharma Mar, S.A. Combination therapy with PM00 104 and another antitumor agent
WO2009138509A1 (en) 2008-05-16 2009-11-19 Pharma Mar, S.A. Multiple myeloma treatments
EP3216793B1 (en) 2008-05-23 2019-03-27 Wyeth LLC Triazine compounds as p13 kinase and mtor inhibitors
JP2011526601A (ja) 2008-07-03 2011-10-13 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性化合物
JP6067222B2 (ja) 2008-07-15 2017-01-25 ジェネンテック， インコーポレイテッド アントラサイクリン誘導体コンジュゲート、その調製方法及び抗腫瘍化合物としてのその用途
KR20110043681A (ko) 2008-07-17 2011-04-27 파르마 마르 에스.에이. 항암 화합물
MX2011006532A (es) 2008-12-19 2011-07-13 Pharma Mar Sa Compuestos anticancerigenos.
WO2010149688A2 (en) 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
EP2563803B1 (en) 2010-04-27 2016-03-09 Pharma Mar S.A. Anticancer steroidal lactones unsaturated in position 7(8)
EP2576569B1 (en) 2010-05-25 2015-01-14 Pharma Mar S.A. Synthetic process for the manufacture of ecteinascidin compounds and intermediates
KR101716804B1 (ko) 2010-11-12 2017-03-15 파르마 마르 에스.에이. 항종양 알칼로이드를 이용한 병용요법
DE102012211024A1 (de) 2012-06-27 2014-01-02 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US10906888B2 (en) 2016-07-14 2021-02-02 Pfizer Inc. Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
IL295044B1 (en) 2023-07-01
KR102510975B1 (ko) 2023-03-16
US20220242883A1 (en) 2022-08-04
US11339180B2 (en) 2022-05-24
IL289963B2 (en) 2023-10-01
TN2019000210A1 (en) 2021-01-07
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
LT4047002T (lt) 2023-05-10
WO2018197663A1 (en) 2018-11-01
JP2022130682A (ja) 2022-09-06
EP3615544B9 (en) 2024-01-03
CN117865987A (zh) 2024-04-12
RS64174B1 (sr) 2023-05-31
EP3395820B1 (en) 2019-05-15
HUE046109T2 (hu) 2020-02-28
CL2019003057A1 (es) 2020-02-21
HUE062157T2 (hu) 2023-10-28
JP2018188431A (ja) 2018-11-29
FI4101855T3 (fi) 2023-09-22
PL3395821T3 (pl) 2019-10-31
AU2022200249B1 (en) 2022-02-10
EP4101855B9 (en) 2024-01-03
TW202202509A (zh) 2022-01-16
EP4101855B1 (en) 2023-08-02
ES2960063T3 (es) 2024-02-29
IL270153A (ar) 2019-12-31
MA44021B1 (fr) 2019-08-30
HRP20191443T1 (hr) 2019-11-15
JP6501947B2 (ja) 2019-04-17
US11713325B2 (en) 2023-08-01
MD4101855T2 (ro) 2023-12-31
MA44020A (fr) 2018-10-31
RS64686B1 (sr) 2023-11-30
IL270153B1 (en) 2023-06-01
JP2023052597A (ja) 2023-04-11
LT3395821T (lt) 2019-08-12
ES2740073T3 (es) 2020-02-05
HRP20231233T1 (hr) 2024-01-19
AU2022200250C1 (en) 2022-06-23
AU2018260314C1 (en) 2022-04-21
HK1255938B (zh) 2020-04-29
EP3395821B1 (en) 2019-05-15
MA44021A (fr) 2019-05-15
TW202344509A (zh) 2023-11-16
PH12019550224A1 (en) 2020-10-12
PL4047002T3 (pl) 2023-07-24
US20210246146A1 (en) 2021-08-12
IL295044B2 (en) 2023-11-01
SI4101855T1 (sl) 2024-03-29
KR20220109495A (ko) 2022-08-04
TN2019000211A1 (en) 2021-01-07
EP4047002A1 (en) 2022-08-24
SI3395821T1 (sl) 2019-09-30
AU2022200250B1 (en) 2022-02-10
AU2022200249C1 (en) 2022-06-23
CN114751920A (zh) 2022-07-15
DK3395821T3 (da) 2019-08-19
US20210070775A1 (en) 2021-03-11
HUE062032T2 (hu) 2023-09-28
HK1255941B (zh) 2020-04-29
EP4101855A1 (en) 2022-12-14
AU2022201657A1 (en) 2022-03-31
PL3615544T3 (pl) 2023-07-17
CO2019011967A2 (es) 2020-02-18
MX2021016058A (es) 2022-02-03
MD4047002T2 (ro) 2023-08-31
ES2944579T3 (es) 2023-06-22
UY37706A (es) 2018-11-30
SG10201913300YA (en) 2020-03-30
IL270153B2 (en) 2023-10-01
KR102492283B1 (ko) 2023-01-27
HRP20230433T1 (hr) 2023-07-07
ME03466B (me) 2020-01-20
CY1121884T1 (el) 2020-10-14
IL289963A (en) 2022-03-01
MX2019012812A (es) 2020-01-14
KR102491180B1 (ko) 2023-01-20
FI3615544T3 (fi) 2023-05-23
CN110621678A (zh) 2019-12-27
ZA201907119B (en) 2021-07-28
KR20210126791A (ko) 2021-10-20
CN114736219A (zh) 2022-07-12
DK3615544T3 (da) 2023-05-30
JP6501946B2 (ja) 2019-04-17
AU2018260314B2 (en) 2021-12-09
MD3395820T2 (ro) 2019-10-31
CA3061518A1 (en) 2018-11-01
LT4101855T (lt) 2023-08-25
JP7422812B2 (ja) 2024-01-26
RS59173B1 (sr) 2019-10-31
EP3395820A1 (en) 2018-10-31
SI3395820T1 (sl) 2019-09-30
EP3615544B1 (en) 2023-03-22
CY1121885T1 (el) 2020-10-14
RS59174B1 (sr) 2019-10-31
HRP20191442T1 (hr) 2019-11-15
BR112019022282A2 (pt) 2020-05-19
IL289963B1 (en) 2023-06-01
FI4047002T3 (fi) 2023-05-22
HUE063736T2 (hu) 2024-01-28
PT3395821T (pt) 2019-08-27
ECSP19083967A (es) 2019-12-27
SI4047002T1 (sl) 2023-07-31
ES2944344T3 (es) 2023-06-20
EP3615544A1 (en) 2020-03-04
MD3615544T2 (ro) 2023-08-31
DK4047002T3 (da) 2023-05-01
US10538535B2 (en) 2020-01-21
JP7186723B2 (ja) 2022-12-09
KR20200012846A (ko) 2020-02-05
DK4101855T3 (da) 2023-11-06
EP4047002B1 (en) 2023-03-08
HUE045641T2 (hu) 2020-01-28
JP2018188432A (ja) 2018-11-29
CY1126061T1 (el) 2023-11-15
ES2741901T3 (es) 2020-02-12
EP3395821A1 (en) 2018-10-31
MY198004A (en) 2023-07-25
TWI742273B (zh) 2021-10-11
LT3615544T (lt) 2023-05-10
MX2021016054A (es) 2022-06-01
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
PT3395820T (pt) 2019-08-07
TWI807411B (zh) 2023-07-01
IL295044A (en) 2022-09-01
RS64200B1 (sr) 2023-06-30
JP2020517709A (ja) 2020-06-18
SI3615544T1 (sl) 2023-07-31
TW201906850A (zh) 2019-02-16
LT3395820T (lt) 2019-08-12
US20180312529A1 (en) 2018-11-01
HRP20230455T1 (hr) 2023-07-21
US11332480B2 (en) 2022-05-17
ME03467B (me) 2020-01-20
SG11201909841RA (en) 2019-11-28
DK3395820T3 (da) 2019-08-12
AU2018260314A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
PH12019550224A1 (en) Antitumoral compounds
GEP20186933B (en) Substituted dihydroisoquinoline compounds
GEP20207111B (en) Heteroaryl compounds for kinase inhibition
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
AU2018258581A8 (en) RAF-degrading conjugate compounds
PH12015502410A1 (en) Biheteroaryl compounds and uses thereof
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
MX2015001720A (es) Hetero-azepinonas sustituidas.
NZ710444A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
GEP201706725B (en) Compounds and compositions as inhibitors of mek
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
GEP20186893B (en) Pyrazines modulators of gpr6
MX2020005707A (es) Profarmacos de creatina, composiciones y metodos de uso de estos.
WO2018146390A8 (fr) Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer
WO2018211324A8 (en) Prodrugs for the treatment of disease
EA201992557A1 (ru) Противоопухолевые соединения
IN2013DE03665A (ar)
UA90817U (uk) Сполука 1,1-діетилкарбокси-2-трифторметил-2-(5'-бромуридил-1'-)етилен з потенційними фізіологічними властивостями
UA90821U (uk) Сполука 1-1-діетилкарбоксі-2-ізопропокси-2-трифторметилетилен з потенційними фізіологічними властивостями
UA91886U (uk) 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол